Acylation of Exenatide by Glycolic Acid and its Anti-Diabetic Activities in db/db Mice
Authors:
- 19 February 2014
- journal article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 31 (8) , 1958-1966
Abstract
To prepare acylated exenatide analogues and investigate their biological properties for guiding the development of PLGA formulations of exenatide. The acylated exenatide analogues were prepared by reaction with glycolic acid (GA), one constitutional unit of PLGA, and characterized by HPLC-MS/MS and Circular Dichroism (CD). The pharmacokinetic properties and anti-diabetic activities were studied in SD rats and db/db mice, respectively. Structural characterizations of the acylated products showed that one to four glycolic acids (GAs) were connected to the primary amine groups of exenatide, and there was a conversion of α-helix to β-sheet to some extent. Pharmacokinetic studies in SD rats revealed that acylated exenatides had a similar Tmax with that of the prototype drug, whereas the Cmax and the AUC values of the adducts were significantly decreased. Biological activity tests demonstrated that exenatide and acylated exenatide analogues had similar in vivo antidiabetic activities in terms of controlling blood glucose concentration, HbA1c level, body weight and food intake. These findings suggest that GA conjugated exenatide had no influence on the peptide efficacy, therefore it’s not necessary to inhibit exenatide acylation in PLGA formulations during the peptide release process.Keywords
This publication has 37 references indexed in Scilit:
- Physiology and Emerging Biochemistry of the Glucagon-Like Peptide-1 ReceptorExperimental Diabetes Research, 2012
- Reversible Blocking of Amino Groups of Octreotide for the Inhibition of Formation of Acylated Peptide Impurities in Poly(Lactide-co-Glycolide) Delivery SystemsAAPS PharmSciTech, 2011
- Controlled Release of Octreotide and Assessment of Peptide Acylation from Poly(D,L-lactide-co-hydroxymethyl glycolide) Compared to PLGA MicrospheresPharmaceutical Research, 2011
- The Current Status of Exenatide Once WeeklyClinical Medicine Insights: Therapeutics, 2011
- A new class of inhibitors of peptide sorption and acylation in PLGAJournal of Controlled Release, 2009
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyThe Lancet, 2008
- Effect of excipients on PLGA film degradation and the stability of an incorporated peptideJournal of Controlled Release, 2007
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006
- Biophysical signatures of noncovalent aggregates formed by a glucagonlike peptide-1 analog: A prototypical example of biopharmaceutical aggregationJournal of Pharmaceutical Sciences, 2005
- Exenatide: NMR/CD evaluation of the medium dependence of conformation and aggregation statePeptide Science, 2004